Top-line findings in Phase 3 batoclimab trial likely by late March
Top-line results from a Phase 3 clinical trial of batoclimab in people with generalized myasthenia gravis (gMG) are expected by the end of March, Roivant, which is developing the antibody therapy through its subsidiary Immunovant, reported. The company said that trial findings will inform further decisions regarding next…